Literature DB >> 15172778

Parkinson's disease.

Ali Samii1, John G Nutt, Bruce R Ransom.   

Abstract

Parkinson's disease is the most common serious movement disorder in the world, affecting about 1% of adults older than 60 years. The disease is attributed to selective loss of neurons in the substantia nigra, and its cause is enigmatic in most individuals. Symptoms of Parkinson's disease respond in varying degrees to drugs, and surgery offers hope for patients no longer adequately controlled in this manner. The high prevalence of the disease, and important advances in its management, mean that generalists need to have a working knowledge of this disorder. This Seminar covers the basics, from terminology to aspects of diagnosis, treatment, and pathogenesis.

Entities:  

Mesh:

Year:  2004        PMID: 15172778     DOI: 10.1016/S0140-6736(04)16305-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  313 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  Computer-Based Visualization System for the Study of Deep Brain Structures Involved in Parkinson's Disease.

Authors:  Juan A Juanes; Pablo Ruisoto; José A Obeso; Alberto Prats; Joan San-Molina
Journal:  J Med Syst       Date:  2015-09-14       Impact factor: 4.460

3.  Detecting freezing of gait with a tri-axial accelerometer in Parkinson's disease patients.

Authors:  Claas Ahlrichs; Albert Samà; Michael Lawo; Joan Cabestany; Daniel Rodríguez-Martín; Carlos Pérez-López; Dean Sweeney; Leo R Quinlan; Gearòid Ò Laighin; Timothy Counihan; Patrick Browne; Lewy Hadas; Gabriel Vainstein; Alberto Costa; Roberta Annicchiarico; Sheila Alcaine; Berta Mestre; Paola Quispe; Àngels Bayes; Alejandro Rodríguez-Molinero
Journal:  Med Biol Eng Comput       Date:  2015-10-01       Impact factor: 2.602

4.  The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease.

Authors:  Eugeniu Vieru; Ayhan Köksal; Belgin Mutluay; Ayten Ceyhan Dirican; Yavuz Altunkaynak; Sevim Baybas
Journal:  Neurol Sci       Date:  2016-01-11       Impact factor: 3.307

5.  Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism.

Authors:  Louise M Collins; Giorgia Dal Bo; Mariangela Calcagno; Jimena Monzón-Sandoval; Aideen M Sullivan; Humberto Gutierrez; Michele Morari; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2015-12-21       Impact factor: 5.590

6.  Lentiviral vectors for the central nervous system.

Authors:  Elena Armandola
Journal:  MedGenMed       Date:  2004-09-24

7.  Brain T1 intensity changes after levodopa administration in healthy subjects: a voxel-based morphometry study.

Authors:  Pilar Salgado-Pineda; Pauline Delaveau; Carles Falcon; Olivier Blin
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

Review 8.  Inhibition of protein misfolding and aggregation by natural phenolic compounds.

Authors:  Zohra Dhouafli; Karina Cuanalo-Contreras; El Akrem Hayouni; Charles E Mays; Claudio Soto; Ines Moreno-Gonzalez
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

9.  Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors.

Authors:  Andrea Crotti; Christopher Benner; Bilal E Kerman; David Gosselin; Clotilde Lagier-Tourenne; Chiara Zuccato; Elena Cattaneo; Fred H Gage; Don W Cleveland; Christopher K Glass
Journal:  Nat Neurosci       Date:  2014-03-02       Impact factor: 24.884

Review 10.  Solvents and Parkinson disease: a systematic review of toxicological and epidemiological evidence.

Authors:  Edward A Lock; Jing Zhang; Harvey Checkoway
Journal:  Toxicol Appl Pharmacol       Date:  2012-12-07       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.